What Tests Should Middle-Aged and Older Adults Undergo After an Atrial Fibrillation Diagnosis?

Atrial fibrillation (AFib) is the most common sustained cardiac arrhythmia, particularly prevalent among middle-aged and older adults. When newly diagnosed in individuals aged 50 years and above, a comprehensive evaluation is essential—not only to confirm the diagnosis but also to identify underlying causes, assess stroke risk, evaluate cardiac structure and function, and guide appropriate management.

Initial assessment begins with a detailed clinical history and physical examination, focusing on symptoms such as palpitations, dyspnea, fatigue, dizziness, or syncope—and crucially, screening for modifiable risk factors including hypertension, diabetes mellitus, obesity, obstructive sleep apnea, excessive alcohol intake, and thyroid dysfunction. A 12-lead electrocardiogram (ECG) remains the gold standard for definitive diagnosis; however, because AFib can be paroxysmal, prolonged rhythm monitoring—via Holter monitoring, event recorders, or implantable loop recorders—may be necessary to capture intermittent episodes.

Echocardiography is routinely recommended to assess left atrial size and volume, left ventricular ejection fraction, valvular structure and function (especially mitral stenosis or regurgitation), and evidence of structural heart disease such as left ventricular hypertrophy or prior myocardial infarction. Cardiac magnetic resonance imaging (CMR) may be considered in select cases to further characterize atrial fibrosis or myocardial scar, particularly when ablation is being contemplated.

Laboratory testing should include thyroid-stimulating hormone (TSH) to exclude hyperthyroidism, serum creatinine and estimated glomerular filtration rate (eGFR) to inform anticoagulant selection and dosing, liver function tests, and fasting lipid profile and hemoglobin A1c to support cardiovascular risk stratification. In patients with unexplained or early-onset AFib, additional evaluation for genetic syndromes or infiltrative diseases—such as cardiac amyloidosis—may be warranted based on clinical clues like low-voltage ECG, disproportionate wall thickening, or heart failure with preserved ejection fraction.

Finally, formal stroke risk assessment using validated tools—most commonly the CHA₂DS₂-VASc score—is integral to determining anticoagulation candidacy. Concurrent bleeding risk assessment (e.g., HAS-BLED score) helps balance thromboembolic and hemorrhagic risks. A multidisciplinary approach—integrating cardiology, electrophysiology, primary care, and anticoagulation management—is key to optimizing long-term outcomes in this heterogeneous patient population.